Next-Generation CRISPR Approaches
Download Whitepaper
| region | na1 |
| portalId | 1769030 |
| formId | 7d08e288-b33f-4e1c-bd5d-251262db95f1 |
| target | services-hubspot-form |
| redirectUrl | https://www.aldevron.com/thank-you/whitepaper-crispr-approach |
Explore Strategies to Advance Therapeutic Programs Supporting Current Regulatory Guidance
Spurred by recent FDA and EMA approvals for CRISPR-based therapies, cell and gene therapy developers have been incorporating various approaches into their manufacturing. Each approach has its own unique set of requirements and limitations.
Read our new whitepaper, Next-Generation CRISPR Approaches, to learn more about:
- AAV and lentivirus delivery approaches
- Non-viral vector-mediated delivery approaches
- A discussion of base editors and prime editors for in vivo therapies
- A review of published next-generation knock-in and enrichment methods
- How we can support your CRISPR pipelines from discovery to commercialization
- NanoplasmidTM—A DNA vector system for improved CRISPR knock-in rates
- Our first-in-class cGMP RNP* manufacturing and analytical service for clinical programs
Download our whitepaper to discover the possibilities of CRISPR.
*Aldevron provides RNP’s only to customers who are dully licensed, including to make, and have made RNPs for their intended use.